• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

Fatigue/Matter Testing


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Completed
Application Number P030025 S021/ PAS002
Date Current Protocol Accepted 09/24/2008
Study Name Fatigue/Matter Testing
General Study Protocol Parameters
Study Design Bench/Lab Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Transit. Adolescent B (as adults) : 18-21 yrs, Adult: >21
Detailed Study Protocol Parameters
Study Design Description This is a simulated use particulates testing, 10-year equivalent pulsatile particulates on a curve testing, 10-year equivalent pulsatile fatigue on a curve testing.
Study Population Description N/A
Sample Size N/A
Data Collection This is a simulated use particulates testing, 10-year equivalent pulsatile particulates on a curve testing, 10-year equivalent pulsatile fatigue on a curve testing.
Follow-up Visits and Length of Follow-up N/A
Interim or Final Data Summary
Interim Safety Information N/A, This is a bench testing study.
Actual Number of Patients Enrolled NA
Actual Number of Sites Enrolled NA
Patient Follow-up Rate NA
Final Safety Findings NA
Final Effect Findings NA
Study Strengths & Weaknesses NA
Recommendations for Labeling Changes None


Fatigue/Matter Testing Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
1 year report 09/24/2009 10/28/2009 Overdue/Received


Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD
20993-0002

Phone: (301) 796-6134
Fax: (301) 847-8140
julie.unger@fda.hhs.gov

Related Links

-
-